The U.S. Supreme Court declined to take up multiple biopharma challenges to the Inflation Reduction Act’s Medicare drug price negotiation program, dealing another blow to brand manufacturers seeking judicial review. The court rejected petitions brought by AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Novartis and Novo Nordisk. With the justices declining review, the legal path for plaintiffs narrows further after lower-court losses and the absence of a circuit split cited in reporting. The decision effectively leaves the IRA negotiation framework in place for the companies that filed suits. For biotech and pharma, the ruling reinforces the near-term policy certainty that influences pricing assumptions in commercialization planning, product launches, and pipeline prioritization. Companies are also likely to keep focusing on operational and litigation strategies within the boundaries set by the courts. While the immediate effect is legal rather than scientific, pricing negotiations remain one of the highest-impact external variables for U.S. oncology and immunology portfolios, especially those facing patent cliffs.